Paper Details

  1. Home
  2. Paper Details

Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.

Author: AndersonJeffrey L, BairTami L, BunchT Jared, CrandallBrian G, DayJohn D, LappeDonald L, MaderKaty M, MahapatraSrijoy, MayHeidi T, MoldenJamie, MuhlesteinJoseph B, MurdockDavid, OsbornJeffrey S, WeissJ Peter

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ranolazine, a drug typically used for angina and ischemia, might be a treatment option for patients experiencing recurrent ventricular tachycardia (VT) despite standard antiarrhythmic-drug (AAD) therapies, leading to repeated implantable cardioverter defibrillator (ICD) shocks. However, its efficacy, outcomes, and tolerance in this specific context remain unclear and require further investigation.
Paper Details　
Original Abstract of the Article :
There are limited options for patients who present with antiarrhythmic-drug (AAD)-refractory ventricular tachycardia (VT) with recurrent implantable cardioverter defibrillator (ICD) shocks. Ranolazine is a drug that exerts antianginal and antiischemic effects and also acts as an antiarrhythmic in is...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1540-8159.2011.03208.x

データ提供：米国国立医学図書館（NLM）

Ranolazine: A Potential Breakthrough for Drug-Refractory Ventricular Tachycardia

This research explores the potential of ranolazine, a drug commonly used for angina, as a therapeutic option for drug-refractory ventricular tachycardia (VT), a condition characterized by rapid and irregular heartbeats that often requires an implantable cardioverter defibrillator (ICD) for treatment. The study highlights the limited treatment options available for patients experiencing recurrent ICD shocks despite standard antiarrhythmic therapy. The researchers explore the potential of ranolazine to reduce VT burden and ICD shocks in these challenging cases. While further research is necessary to confirm its efficacy and safety, this study provides hope for patients with drug-refractory VT, offering a potential new avenue for treatment.

Ranolazine: A New Hope for Difficult-to-Treat Heart Rhythms

The study suggests that ranolazine may be a promising treatment option for drug-refractory ventricular tachycardia, offering hope for patients who have exhausted standard antiarrhythmic therapies. This finding underscores the need for further investigation into the potential of ranolazine for this specific condition.

Understanding the Potential of Ranolazine for Heart Health

This research highlights the need for continued exploration of new therapeutic strategies for complex heart conditions. Patients with drug-refractory ventricular tachycardia should consult with their healthcare providers to discuss the latest advancements and potential treatment options, including ranolazine. Remember, every step towards improved heart health is a valuable journey.

Dr.Camel's Conclusion

This research is a beacon of hope in the vast desert of difficult-to-treat heart conditions. Ranolazine, like a refreshing oasis, offers potential relief for patients struggling with drug-refractory ventricular tachycardia. As we continue to explore its potential, we move closer to finding effective treatments for even the most challenging heart conditions.
Date :
  1. Date Completed 2012-04-24
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

21895727

DOI: Digital Object Identifier

10.1111/j.1540-8159.2011.03208.x

Related Literature

Article Analysis
・Side Effects of ranolazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.